Background: Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility in women of childbearing age. Emerging evidence has demonstrated that melatonin (MT) is a promising therapeutic drug for PCOS. However, the specific therapeutic mechanisms are largely unknown. This study explores MT's potential pharmacological targets and pathways for PCOS using a systematic pharmacology approach.Methods: MT's potential pharmacological targets were obtained from the Traditional Chinese Medicine Systems Pharmacology (TCMSP), DrugBank, PharmMapper, and SwissTargetPrediction databases. The PCOS targets were obtained from the GeneCards, DisGeNET, and National Center for Biotechnology Information (NCBI) Gene databases. The protein-protein interaction (PPI) network was constructed with the STRING database. The Cytoscape plugin "CytoHubba" identified the hub genes using a Maximal Clique Centrality (MCC) topological analysis. The predicted therapeutic targets were imported into the Database for Annotation, Visualization and Integrated Discovery (DAVID) tools to perform the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses. The results were visualized by an online bioinformatics tool, and the network construction was visualized using Cytoscape software. Molecular docking was performed via AutoDock Vina and PyMOL.Results: A total of 37 potential therapeutic targets were obtained, which were involved in biological processes (BP) closely related to hormone synthesis and transcriptional regulation in cells, such as the intracellular steroid hormone receptor signaling pathway, steroid catabolic process, and regulation of transcription from RNA polymerase II promoter. Using the Cytoscape network analysis, ten hub targets [ESR1, androgen receptor (AR), matrix metalloproteinase 9 (MMP9), CYP19A1, IGF1R, progesterone receptor (PGR), CYP1A1, NR3C1, ESR2, MDM2] were discovered by the MCC algorithm of the "CytoHubba" plugin. Molecular docking also showed high affinity between these ten hub targets with MT, indicating that these targets might play key roles in treating PCOS. The top ten KEGG pathways interacted with the 37 potential therapeutic targets and were classified into four functional modules: circadian rhythm, reproductive process, metabolic process, and oocyte maturation.Conclusions: As a critical rhythm synchronizer, MT may alleviate symptoms of reproductive and metabolic disorders of PCOS systemically. At a localized level, it may protect oocytes from oxidative stress due to its strong antioxidant effects.